Phaseline

Companies › invoX Pharma

invoX Pharma: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
FS222–Phase 1Advanced CancerOct 2027
Pembrolizumab (FS120)
Programmed cell death protein 1 inhibitor
PDCD1Phase 1Advanced Cancer–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04648202Pembrolizumab (FS120)Phase 1Advanced CancerOncologyJan 2025
NCT04740424FS222Phase 1Advanced CancerOncologyOct 2027

Targets

PDCD1 (1)

Companies with the same targets

Akeso Sichuan Baili Pharmaceutical Innovent Biologics (Suzhou) Shanghai Henlius Biotech AstraZeneca Shenyang Sunshine Pharmaceutical Regeneron Pharmaceuticals Ono Pharmaceutical Mabwell (Shanghai) Bioscience Johnson & Johnson (Janssen)

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.